Immunology and inflammation Archives -

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

https://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/

Avillion/Merck psoriasis nanobody hits the mark in phase 2

https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/

Lilly cuts a $960m deal with Rigel on RIP kinase

https://pharmaphorum.com/news/lilly-cuts-a-960m-deal-with-rigel-on-rip-kinase/

Vicore builds case for C21 drug in hospitalised COVID-19 patients

https://pharmaphorum.com/news/vicore-builds-case-for-c21-drug-in-hospitalised-covid-19-patients/

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

https://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/

Sanofi’s Dupixent backed for nasal polyps use in Europe

https://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/

Next gen psoriasis drugs show superiority to Stelara

https://pharmaphorum.com/news/janssen-guselkumab/

Search